Skip to contentpdufa.bio

JUVMO (tavapadon): FDA NDA 220415

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 220415 is the FDA application for JUVMO (tavapadon). The FDA's Orange Book lists the applicant of record as ABBVIE INC and the first approval on it as Sep 25, 2026. Owner today: AbbVie Inc. (NYSE: ABBV).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220415 · Orange Book NDA 220415

Names for this drug

Brand name (FDA)JUVMO
Orange Book trade name: JUVMO
Active ingredient (FDA)TAVAPADON

Who holds the application

FDA applicant of recordABBVIE INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayAbbVie Inc. (ABBV)
Source: AbbVie press release, Sep 28, 2026
“AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved”
Earlier / partnerCerevel Therapeutics (ticker at the time: CERE): acquired by the current owner, Aug 1, 2024
Source: AbbVie press release, Aug 1, 2024
“AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE).” … “Tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of Parkinson's disease”

Products on NDA 220415 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001JUVMO (COPACKAGED)TABLET;ORAL0.25MG;1MGSep 25, 2026
002JUVMOTABLET;ORAL5MGSep 25, 2026
003JUVMOTABLET;ORAL10MGSep 25, 2026
004JUVMOTABLET;ORAL15MGSep 25, 2026

FDA decisions we track for this drug

JUVMO (tavapadon)ABBV · Decided

Drug page: /drug/tavapadon

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.